UNSPSC 51172301: Deferoxamine

This classification denotes a metal chelator with the molecular formula C25H48N6O8, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier J06Y7MXW4D, chemically known as 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy- but more generally known as deferoxamine, which bears U.S. National Institutes of Health Compound Identifier 2973. European Medicines Agency schedules Deferoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06942MIG.

World Health Organization schedules deferoxamine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. DEFEROXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51172301 Deferoxamine is a Commodity code that in recent state and local activity tracks pharmaceutical procurement, though the narrow product name does not align with the breadth of what jurisdictions are actually soliciting. State and local buyers under this code purchase generic pharmaceuticals, over-the-counter products, and specialized pharmaceutical services including specimen collection, drug screening and confirmation testing, and direct-to-manufacturer prescription fulfillment models. Issuing bodies include state health and human services departments, county criminal justice and community supervision agencies, and cooperative purchasing alliances representing multiple state and local participants. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers multi-state pharmaceutical contracts on behalf of participating state and local government facilities across multiple jurisdictions including Oregon. Collin County Community Supervision and Corrections Department in Texas solicits drug testing services with specimen collection and lab confirmation capabilities, including immunoassay screening with LC/MS/MS or GC/MS confirmation and alternative testing methodologies. The Texas Health and Human Services Commission pursues direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity spans Texas and the Upper Midwest, with Minnesota's cooperative purchasing vehicle serving a multi-state footprint. The Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802), issued January 20, 2026, with proposals due March 26, 2026, seeks manufacturers for two-year contracts effective July 1, 2026, requiring cGMP certification, Drug Supply Chain Security Act compliance, and distribution through three authorized wholesalers; evaluation weights price competitiveness at 75 percent and administrative compliance at 20 percent combined. Collin County's RFP 2026-327 for offender specimen collection and drug testing services, posted July 9, 2026, with proposals due July 23, 2026, covers two collection sites with approximately 25,031 annual tests at an estimated contract value of $600,000 over two years with three optional one-year renewals; evaluation emphasizes vendor understanding, firm qualifications, references, and cost across Phase 1 scoring and optional Phase 2 demonstrations. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, reflecting early-stage market research prior to formal solicitation.